Internal medicine

The Aging Revolution: Growing old in America becoming more dignified, but with senior population booming, is nation’s health system prepared?

Retrieved on: 
tisdag, juni 4, 2024

The apathy often resulted in inferior care for aging adults who frequently struggled with multiple chronic conditions that were largely ignored by physicians, who saw pain and suffering as inevitable to the aging process.

Key Points: 
  • The apathy often resulted in inferior care for aging adults who frequently struggled with multiple chronic conditions that were largely ignored by physicians, who saw pain and suffering as inevitable to the aging process.
  • The book, published by Skyhorse Publishing , analyzes the social action movements since the 1970s that have dramatically improved the quality of life and life expectancy of adults.
  • The emergence and expansion of palliative care programs to manage patients’ pain and improve quality of life, a specialized medical practice that has spread to nearly every US health system.
  • New initiatives that train, partially compensate and support millions of family caregivers tending to loved ones in the home.

Dr. Michael Warhurst Joins Physician Partners of America- North Florida

Retrieved on: 
torsdag, juni 13, 2024

JACKSONVILLE, Fla., June 13, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Michael Warhurst, DO, has joined the company's Jacksonville and Orange Park pain management practices. He began seeing patients in April at the offices located at 11705 San Jose Blvd #110, Jacksonville, FL 32223 and 1731 Wells Road, Suite 100, Orange Park, FL 32073.

Key Points: 
  • Interventional pain management physician now seeing patients in North Florida area.
  • JACKSONVILLE, Fla., June 13, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Michael Warhurst, DO, has joined the company's Jacksonville and Orange Park pain management practices.
  • "Our North Florida clinics are key assets to our rapidly expanding organization.
  • His strong desire to help people is what drove him to become a pain management physician.

EQS-News: Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Retrieved on: 
tisdag, juni 4, 2024

This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.

Key Points: 
  • This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.
  • This test integrates the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm.
  • This combination enables precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.
  • Sensitivity for Advanced Precancerous Lesions: 82.2% (95% confidence interval: 75.0-88.0)
    This study highlighted the significant advantage of the multimodal screening test over existing methods, particularly in detecting advanced precancerous lesions.

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Retrieved on: 
måndag, juni 3, 2024

Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.

Key Points: 
  • Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.
  • Treatment with mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo, as measured by the TRR endpoint.
  • Agios plans to present a more detailed analysis of the Phase 3 ENERGIZE-T data at an upcoming medical meeting.
  • The event can be accessed under “Events & Presentations” in the Investors and Media section of the company's website at www.agios.com .

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Retrieved on: 
måndag, juni 3, 2024

BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online. This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.

Key Points: 
  • This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.
  • The combined analysis involves 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States, including previously unexamined and unreported samples, highlighting the remarkable efficacy of Mainz Biomed's multimodal screening test.
  • This test integrates the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm.
  • This combination enables precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Retrieved on: 
söndag, juni 2, 2024

The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.

Key Points: 
  • The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
  • “The diagnosis of HAE patients with normal C1-inhibitor is complicated and often delayed by the lack of an easily measurable biochemical marker.
  • One patient experienced gastrointestinal symptoms upon initiation, which became milder after the first two weeks and did not lead to treatment discontinuation.
  • Additional new results presented at EAACI demonstrate the adverse health outcomes associated with attenuated androgen use as a prophylactic treatment for HAE.

Dr. Phillip Oberg Joins Utah Gastro in St. George

Retrieved on: 
torsdag, maj 30, 2024

St. George, UT, May 30, 2024 (GLOBE NEWSWIRE) -- Utah Gastroenterology welcomes the addition of Dr. Phillip Oberg, a board certified professional who treats all gastrointestinal diseases, while specializing in performing EGD, colonoscopy, ERCP, video capsule endoscopy, fibroscan, and treating esophageal dysmobility and liver disease.

Key Points: 
  • St. George, UT, May 30, 2024 (GLOBE NEWSWIRE) -- Utah Gastroenterology welcomes the addition of Dr. Phillip Oberg, a board certified professional who treats all gastrointestinal diseases, while specializing in performing EGD, colonoscopy, ERCP, video capsule endoscopy, fibroscan, and treating esophageal dysmobility and liver disease.
  • Dr. Oberg is board certified in Internal Medicine, received his undergraduate degree from Utah Valley University, and his medical degree from Touro University Nevada College of Osteopathic Medicine.
  • I have always been interested in our organ systems that are able to take our food and provide nutrients in a dynamic functioning body,” says Dr. Oberg.
  • Utah Gastro is at 368 E. Riverside Dr., Suite A, St. George, UT , and is open Monday through Friday, 8am to 5pm.

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

Retrieved on: 
fredag, maj 31, 2024

The results of KONFIDENT were simultaneously published in The New England Journal of Medicine.

Key Points: 
  • The results of KONFIDENT were simultaneously published in The New England Journal of Medicine.
  • Subgroup analyses showed a consistency of treatment effect in among attacks regardless of attack severity, attack location, use of long-term prophylaxis, or geography.
  • There were no patient withdrawals due to any adverse events and no treatment-related serious adverse events (SAEs) were observed.
  • Treatment-related adverse event rates were 2.3% for 300 mg sebetralstat, 3.2% for 600 mg sebetralstat, and 4.8% for placebo.

Frailty Is an Important Factor in Clinical Interventions for Older Adults, According to New Research From VillageMD

Retrieved on: 
torsdag, maj 30, 2024

A new study published in the Journal of General Internal Medicine found that the efficacy of clinical interventions often varied by frailty levels, demonstrating that frailty is an important factor to consider in recommending treatments in older adults.

Key Points: 
  • A new study published in the Journal of General Internal Medicine found that the efficacy of clinical interventions often varied by frailty levels, demonstrating that frailty is an important factor to consider in recommending treatments in older adults.
  • The research was conducted by a team including members from the VillageMD Research Institute and is titled, “Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review.” Researchers summarized the impact of patients’ frailty status on the effectiveness of pharmacological, non-pharmacological, and multicomponent clinical interventions.
  • “We need more studies to understand which treatment works and how treatment benefits and harms vary by patients’ frailty level.
  • A validated frailty instrument should be included in randomized controlled trials enrolling older adults to facilitate generation of high-quality evidence.

Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors

Retrieved on: 
torsdag, maj 30, 2024

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months.
  • “We are thrilled to welcome Dr. Jacobson to our Board of Directors,” said Philip J.
  • Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio.
  • “I am excited to join Lobe Sciences at such a pivotal time in the company’s growth,” said Dr. Jacobson.